4,870 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by May Hill Capital LLC

May Hill Capital LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,870 shares of the company’s stock, valued at approximately $419,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. purchased a new position in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Center for Financial Planning Inc. raised its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after buying an additional 123 shares during the period. Dunhill Financial LLC raised its stake in shares of Novo Nordisk A/S by 196.8% in the third quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock valued at $56,000 after buying an additional 311 shares during the period. Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares during the last quarter. Finally, Hager Investment Management Services LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth $46,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 21st. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Up 0.4 %

Shares of NYSE:NVO opened at $69.58 on Tuesday. The company has a market cap of $312.24 billion, a price-to-earnings ratio of 21.15, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a one year low of $66.88 and a one year high of $148.15. The firm has a fifty day moving average price of $82.15 and a two-hundred day moving average price of $98.17. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.